Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shin Nippon Biomedical Laboratories, Ltd. ( (JP:2395) ) has issued an update.
Shin Nippon Biomedical Laboratories, Ltd. has revised its consolidated earnings forecast for the fiscal year ending March 31, 2025, citing better-than-expected sales and orders in its nonclinical CRO business. The forecast revisions include an increase in revenue and profits, attributed to lower operational costs at its US subsidiary and higher profit shares from equity method investments. This positive outlook is based on a stable exchange rate of 145.00 yen to the US dollar.
More about Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. operates in the nonclinical contract research organization (CRO) industry. The company primarily focuses on providing preclinical research services, with a significant emphasis on its nonclinical CRO business.
YTD Price Performance: -0.42%
Average Trading Volume: 317,328
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: Yen69.15B
For a thorough assessment of 2395 stock, go to TipRanks’ Stock Analysis page.